# TransMedics Group, Inc. (TMDX)

- Sector: Healthcare · Industry: Medical Devices
- SEC CIK: 0001756262 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001756262))
- Full page: https://inspectstocks.com/stocks/tmdx
- Data as of: price 2026-09-29; newest filing used 2026-08-04; latest fiscal period ended 2026-06-30

## Grade

**B+** on the growth-and-cash rubric, 4 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | passed | $668.5M | $151.1M |
| Revenue growing recently | passed | $668.5M | $605.5M |
| Free cash flow positive | passed | $79M |  |
| Free cash flow growing overall | passed | $79M | -$40.8M |
| Free cash flow growing recently | failed | $79M | $133.6M |

Business quality (the + / − mark): 5 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed | 22.7% |  |
| Healthy profit margin | passed | 22.7% |  |
| Strong operating margin | failed | 12.2% |  |
| Good return on equity | passed | 32.1% |  |
| Debt under control | passed | 0.99 |  |
| Turns sales into cash | passed | 11.8% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $668.5M |
| Net income, trailing twelve months | $151.7M |
| Free cash flow, trailing twelve months | $79M |
| Net margin | 22.7% |
| Operating margin | 12.2% |
| Return on equity | 32.1% |
| Debt to equity | 0.99 |
| Diluted EPS, trailing twelve months | $3.86 |
| Share price | $84.05 |
| Market value | $2.9B |
| Price / earnings | 21.8x |
| Price / sales | 4.4x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/tmdx)
- [Financial statements](https://inspectstocks.com/stocks/tmdx/financials)
- [Competitors](https://inspectstocks.com/stocks/tmdx/peers)
- [Earnings](https://inspectstocks.com/stocks/tmdx/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.